Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!

TRK fusion–positive solid tumors represent a unique molecular subgroup of tumors that are susceptible to larotrectinib therapy.

This pooled analysis of three phase I/II trials was designed to evaluate the benefit of larotrectinib in patients with TRK fusion–positive solid tumors. The objective response rate was 79%, with a complete response rate of 16%. The safety profile was manageable.

https://www.thelancet.com/action/showPdf?pii=S1470-2045%2819%2930856-3#seccestitle10

Spread the word. Share this post!